Status:
COMPLETED
Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
Lead Sponsor:
Profil Institut für Stoffwechselforschung GmbH
Collaborating Sponsors:
Sanofi
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
Detailed Description
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
Eligibility Criteria
Inclusion
- Patients with type 2 diabetes mellitus diagnosed at least one year before the screening visit not previously treated with glitazones, insulin or GLP-1 agonists
- Inadequately controlled diabetes mellitus
Exclusion
- Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or secondary forms of diabetes such as due to pancreatitis
Key Trial Info
Start Date :
December 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT01910194
Start Date
December 1 2013
End Date
October 1 2014
Last Update
January 22 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Josef-Hospital, University Hospital, Ruhr
Bochum, Germany, 44791
2
Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany, 41460